Latest news with #ClearPoint
Yahoo
23-06-2025
- Business
- Yahoo
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington's disease. A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint's first 'meaningful partner asset.' ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy's effectiveness. The FDA's support might result in the approval by the end of 2026, which would have a big effect on ClearPoint's financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery. According to Lake Street, this regulatory milestone increases clarity on ClearPoint's contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130. While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
16-06-2025
- Business
- Cision Canada
INTOUCH INSIGHT LTD. ANNOUNCES A DEFINITIVE AGREEMENT TO ACQUIRE THE ASSETS OF CLEARPOINT SOLUTIONS US, LLC BASED IN ATLANTA, GEORGIA
OTTAWA, ON, June 16, 2025 /CNW/ - Intouch Insight Ltd. (Intouch or the Company) (TSXV: INX) (OTCQX: INXSF) announced today that it has entered into a definitive agreement, for an initial cash payment of USD $250,000, to acquire all assets of ClearPoint Solutions US, LLC (ClearPoint), a merchandising company specializing in in-store services such as merchandising and re-branding since 2022. The definitive agreement was executed today. Subject to customary closing conditions, the acquisition is expected to close on July 3, 2025. "This acquisition represents an exciting opportunity to accelerate and de-risk our continued expansion into the merchandising market," stated Cameron Watt, President & Chief Executive Officer of Intouch. "ClearPoint has successfully navigated its formative years and, with the right strategic direction and support, is primed for substantial growth. Led by Sam Hersey, who brings over 25 years of extensive experience in the retail industry, we're thrilled to welcome both a robust team and established revenue streams that will enhance our merchandising business." The acquisition's purchase price combines an initial cash payment of USD $250,000 upon closing with contingent payments based on a share of future operating profits in the merchandising business over a four-year period post-closing. The initial cash outlay will be covered by Intouch's existing cash reserves. ClearPoint is at arm's length to Intouch, and no finder's fees will be paid by Intouch. Following the closing, ClearPoint President Sam Hersey will continue with Intouch in his leadership role in the merchandising business. "My decision to sell the assets of ClearPoint was thoughtful and deliberate. I am confident the synergies with Intouch will enable the merchandising business to achieve accelerated growth and establish an expanded presence in the market," commented Sam Hersey, Founder & President of ClearPoint. "Intouch's existing infrastructure and shared industry focus provide an immediate platform, allowing the ClearPoint team to concentrate fully on client acquisition and satisfaction." Watt further emphasized, "This acquisition is a direct alignment with our strategic goal of renewing our presence in the merchandising market, creating a new avenue for growth in our services revenues. It also immediately provides us with an established customer base and a skilled field execution team, mitigating the risks typically associated with building a division from the ground up." About Intouch Insight Intouch Insight offers a complete portfolio of customer experience management (CEM) products and services that help global brands delight their customers, strengthen brand reputation and improve financial performance. Intouch helps clients collect and centralize data from multiple customer touch points, gives them actionable, real-time insights, and provides them with the tools to continuously improve customer experience. Founded in 1992, Intouch is trusted by over 300 of North America's most-loved brands for their customer experience management, customer survey, mystery shopping, mobile forms, operational and compliance audits, geolocation data capture and event marketing automation solutions. For more information, visit Certain statements included in this news release contain forward looking statements that are made of the date hereof, which by their nature are necessarily subject to risks and uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events, including the acquisition, future revenues and references to the Company's expansion and growth of the business and operations, and are based on information currently available to the Company and on hypotheses which it considers to be reasonable; however, management warns the reader that hypotheses relative to future events which are beyond the control of management could prove to be false, given that they are subject to certain risks and uncertainties. Please refer to the risks set forth in the Company's most recent annual MD&A and the Company's continuous disclosure documents that can be found on SEDAR at The Company does not intend, and disclaims any obligation, except as required by law, to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Yahoo
16-06-2025
- Business
- Yahoo
INTOUCH INSIGHT LTD. ANNOUNCES A DEFINITIVE AGREEMENT TO ACQUIRE THE ASSETS OF CLEARPOINT SOLUTIONS US, LLC BASED IN ATLANTA, GEORGIA
OTTAWA, ON, June 16, 2025 /CNW/ - Intouch Insight Ltd. (Intouch or the Company) (TSXV: INX) (OTCQX: INXSF) announced today that it has entered into a definitive agreement, for an initial cash payment of USD $250,000, to acquire all assets of ClearPoint Solutions US, LLC (ClearPoint), a merchandising company specializing in in-store services such as merchandising and re-branding since 2022. The definitive agreement was executed today. Subject to customary closing conditions, the acquisition is expected to close on July 3, 2025. "This acquisition represents an exciting opportunity to accelerate and de-risk our continued expansion into the merchandising market," stated Cameron Watt, President & Chief Executive Officer of Intouch. "ClearPoint has successfully navigated its formative years and, with the right strategic direction and support, is primed for substantial growth. Led by Sam Hersey, who brings over 25 years of extensive experience in the retail industry, we're thrilled to welcome both a robust team and established revenue streams that will enhance our merchandising business." The acquisition's purchase price combines an initial cash payment of USD $250,000 upon closing with contingent payments based on a share of future operating profits in the merchandising business over a four-year period post-closing. The initial cash outlay will be covered by Intouch's existing cash reserves. ClearPoint is at arm's length to Intouch, and no finder's fees will be paid by Intouch. Following the closing, ClearPoint President Sam Hersey will continue with Intouch in his leadership role in the merchandising business. "My decision to sell the assets of ClearPoint was thoughtful and deliberate. I am confident the synergies with Intouch will enable the merchandising business to achieve accelerated growth and establish an expanded presence in the market," commented Sam Hersey, Founder & President of ClearPoint. "Intouch's existing infrastructure and shared industry focus provide an immediate platform, allowing the ClearPoint team to concentrate fully on client acquisition and satisfaction." Watt further emphasized, "This acquisition is a direct alignment with our strategic goal of renewing our presence in the merchandising market, creating a new avenue for growth in our services revenues. It also immediately provides us with an established customer base and a skilled field execution team, mitigating the risks typically associated with building a division from the ground up." About Intouch InsightIntouch Insight offers a complete portfolio of customer experience management (CEM) products and services that help global brands delight their customers, strengthen brand reputation and improve financial performance. Intouch helps clients collect and centralize data from multiple customer touch points, gives them actionable, real-time insights, and provides them with the tools to continuously improve customer experience. Founded in 1992, Intouch is trusted by over 300 of North America's most-loved brands for their customer experience management, customer survey, mystery shopping, mobile forms, operational and compliance audits, geolocation data capture and event marketing automation solutions. For more information, visit Certain statements included in this news release contain forward looking statements that are made of the date hereof, which by their nature are necessarily subject to risks and uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such statements reflect the Company's current views with respect to future events, including the acquisition, future revenues and references to the Company's expansion and growth of the business and operations, and are based on information currently available to the Company and on hypotheses which it considers to be reasonable; however, management warns the reader that hypotheses relative to future events which are beyond the control of management could prove to be false, given that they are subject to certain risks and uncertainties. Please refer to the risks set forth in the Company's most recent annual MD&A and the Company's continuous disclosure documents that can be found on SEDAR at The Company does not intend, and disclaims any obligation, except as required by law, to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE Intouch Insight Ltd. View original content:
Yahoo
11-06-2025
- Business
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
09-06-2025
- Business
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
